# ANTICIPATE (NCT04813107)

> A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04813107
- Phase: PHASE1, PHASE2
- Status: UNKNOWN
- Sponsor: Jiangsu Yahong Meditech Co., Ltd aka Asieris
- Conditions: Muscle Invasive Bladder Cancer
- Interventions: APL-1202 in combination with tislelizumab; Tislelizumab alone
- Enrollment: 79
- Primary outcome: Adverse events (AE) and serious adverse events (SAE).
- Primary outcome: The RP2D of APL-1202 in combination with tislelizumab.
- Primary outcome: The rate of pathologic complete response (pCR) in Phase 2.

## Indexed commentary on ANTICIPATE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=anticipate-nct04813107